NCT05327010 2026-03-19
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06762808 2025-08-15
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT02921919 2022-08-24
Open-Label Extension and Safety Study of Talazoparib
Pfizer
Phase 2 Completed